Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention

This cohort study found that the AQUILA trial criteria classified approximately 3 times more patients with SMM as having high risk compared with the 2/20/20 model and captured a group with substantially lower progression risk. These results suggest that the 2/20/20 model more accurately identifies a truly high-risk group with SMM, for whom early treatment is more likely to be beneficial.